Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 9/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 7/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | MELK | Q14680 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469964 | 1.00 | FGFR3 (0.44) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL16049913 | 1.00 | FGFR3 (0.44) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL17470117 | 0.95 | FGFR3 (0.47) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL17537596 | 0.95 | FGFR3 (0.47) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL16069923 | 0.92 | FGFR3 (0.44) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL16069698 | 0.92 | JAK3 (0.46) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL17470080 | 0.92 | JAK3 (0.46) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL16049926 | 0.91 | FGFR3 (0.40) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL17469983 | 0.91 | FGFR3 (0.40) | FGFR3KCNH2KDRFGFR1FGFR2 | |
| SCHEMBL16069724 | 0.91 | FGFR3 (0.40) | FGFR3KCNH2KDRFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970120-B1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LTD (CN) | 2018-09-12 | — | — | EP | disclosed |
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| EP-2970120-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | Hutchison Medipharma Limited (CN) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014139145-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139145-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | FGFR3, FGFR1, FGFR4 | FGFR3 1/4885KCNH2 2589/4885KDR 66/4885 |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | FGFR3 1/4885KCNH2 2621/4885KDR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.